Product Description
MB-109 combines MB-101 (IL13Ralpha2-targeted CAR-T cells) CAR T cell therapy with MB-108 (C134 oncolytic virus). The combination is designed to leverage MB-108 to make cold glioblastoma tumors "hot," and thereby improve the efficacy of MB-101 CAR-T cell therapy. (Sourced from: https://www.mustangbio.com/pipeline/#:~:text=C134%20or%20MB%2D108&text=In%20February%202019%2C%20Mustang%20Bio,of%20all%20primary%20brain%20tumors.)
Mechanisms of Action: Cell Therapy, IL13
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fortress Biotech
Company Location: Eastern America
Company CEO: Alexandra MacLean
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Glioblastoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|